The recent advent of lenalidomide has been a major breakthrough in IPSS low-and intermediate-1-risk myelodysplastic syndrome (MDS) with del 5q syndrome, as this drug leads to RBC transfusion independence in twothirds of them. 1 The kinetics of response to lenalidomide and in vitro studies suggested a selective inhibitory effect of lenalidomide on the clone with 5q deletion. 2, 3 However, at least one-third of MDS with del 5q have higher-risk IPSS, that is, IPSS high or intermediate-2. del 5q is also a frequent finding in AML in the elderly. Higher risk and AML with del 5q carry a poor prognosis, due in particular to their poor response to anthracycline-AraC chemotherapy in the case of AML and to azacytidine in the case of MDS. 4 In a recent phase II study conducted in 47 patients with high-and intermediate-2-risk MDS with del 5q, 6 of the 9 patients with isolated del 5q achieved CR, whereas only 1 of the patients with one or several chromosomal abnormalities in addition to del 5q responded. 5 Finally, in higher-risk MDS (including those with del 5q), allo-SCT remains the only curative option, but the relapse rate remains important after transplantation, especially in the case of the non-myeloablative conditioning regimen. We report the induction of hematological and cytogenetic CR by lenalidomide in a patient with AML and del 5q relapsing after non-myeloablative SCT.
A 70-year-old woman presented with sAML (preceded by an 8-month MDS phase) 13 years after the treatment of a breast carcinoma by chemotherapy consisting of CY, epirubicin, 5-FU and radiotherapy. BM karyotype was 46 XX, del(5)(q31), del (21)(q22). Hematological and cytogenetic CR was achieved after three courses of a combination of low-dose AraC (10 mg/m 2 on days 1-14) and arsenic trioxide (0.25 mg/kg on days 1-5 and days 8-12). 6 The patient then received non-myeloablative allo-SCT from a sibling donor (her brother) after a fludarabine (25 mg/m 2 / day for 4 days), CY (60 mg/kg for 2 days) and ATG (2.5 mg/kg for 2 days) conditioning regimen. GVHD prophylaxis consisted of CYA and mycophenolate mofetil, continued until days 170 and 70 post transplantation, respectively. The patient experienced no GVHD and was still in hematological and cytogenetic CR 12 months after transplant. Two years post transplant, she developed mild cytopenias (ANC 1.7 Â 10 9 per l, plt 115 Â 10 9 per l and hemoglobin 10.6 g/dl). An excess of marrow blasts (7 and 8%) with recurrence of the 5q deletion associated with a 21q deletion (in 60% of the mitoses) was observed in two sequential marrow aspirates, using conventional cytogenetic and FISH analyses (Figure 1) . At that time, chimerism was then 60% donor.
Lenalidomide was started at a dose of 10 mg/day for 21 days every 28 days. After three cycles, the hemoglobin level had increased to 12 g/dl and the patient was in complete hematological remission with partial cytogenetic response (del 5q being still observed in 25% of the cells by FISH analysis). Finally, complete cytogenetic response was achieved after six cycles of lenalidomide. It is noteworthy that marrow chimerism using FISH, using labeled X and Y chromosome probes, increased from 60% donor at the time of relapse to 87% donor at the time of cytogenetic CR and from 60 to 75% in CD3 þ cells.
Grade 3 neutropenia (NCI CTCAE version 3.0), responding to G-CSF, and grade 2 thrombocytopenia developed during the first few weeks of treatment, but after three cycles of lenalidomide, the blood cytopenias disappeared without further growth factor requirement. Ten months after the introduction of lenalidomide, the patient was alive in complete hematological and cytogenetic remission, still on lenalidomide 10 mg/day for 21 days every 28 days.
To our knowledge, this is the first report of a patient with MDS or AML with del 5q relapsing after allo-SCT treated with lenalidomide. In this patient, lenalidomide at a 10 mg daily dose was well tolerated and led to a complete hematological and cytogenetic response associated with an increase in donor chimerism from 60 to 90%.
The mechanism of action of lenalidomide in patients with del 5q remains unclear. The kinetics of response to lenalidomide in patients with MDS and 5q deletion (that is, the occurrence of neutropenia and thrombocytopenia, often profound, followed by hematopoietic recovery) and in vitro studies suggest a selective inhibitory effect of lenalidomide on the clone with 5q deletion. Nonetheless, other studies suggesting that lenalidomide might also act as an immunomodulatory drug have been published, focusing on the putative role of lenalidomide on natural killer (NK) and T cells. NK cells are critical in host defense against malignant transformation and are potent antileukemic cytotoxic effectors. The cytolytic function and proliferative capacities of NK cells in response to activation by cytokines are profoundly altered in MDS. 7 It has been suggested that the impairment of NK cytolytic function in MDS, which accompanies disease progression, could be restored with lenalidomide. 8 Moreover, NK alloreactivity after allo-SCT has a major role in the graft-versus-leukemia effect without causing GVHD. In this case, it remains unknown whether CR was obtained by the direct cytotoxicity of lenalidomide on the del 5q clone or by immunomodulation.
A potential antileukemic role for lenalidomide after SCT should be further investigated in patients carrying del 5q deletion, either isolated or associated with other cytogenetic abnormalities.
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